Using advanced technology to improve the diagnosis of pancreatic cancer
Combining Machine Learning and Nanofluidic Technology for The Multiplexed Diagnosis of Pancreatic Adenocarcinoma
This study is working on a new, gentle way to help find early signs of pancreatic cancer by looking at tiny particles in your blood, which could lead to quicker and more accurate diagnoses for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11095725 on NIH RePORTER |
What this research studies
This research focuses on developing a non-invasive diagnostic method for pancreatic ductal adenocarcinoma (PDAC) by utilizing machine learning and nanofluidic technology. It aims to analyze circulating tumor-derived extracellular vesicles (EVs) found in blood samples to identify early-stage pancreatic cancer more accurately than current methods. By isolating and examining the RNA and protein markers from these EVs, the research seeks to enhance the sensitivity and specificity of pancreatic cancer detection, potentially leading to earlier diagnosis and better treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for pancreatic cancer, such as those with a family history of the disease or specific genetic predispositions.
Not a fit: Patients who have already been diagnosed with advanced pancreatic cancer and are not candidates for curative surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of pancreatic cancer, significantly improving patient survival rates.
How similar studies have performed: Previous research has shown promise in using liquid biopsy techniques for cancer detection, indicating that this approach may lead to significant advancements in pancreatic cancer diagnostics.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Issadore, David Aaron — University of Pennsylvania
- Study coordinator: Issadore, David Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.